Adjuvant chemotherapy increases survival and decreases recurrence in stage HA colon cancer

Hepato-Gastroenterology

Volumn 59, Issue 120, 2012, Pages 2466-2471

  Yun, HaeRan ^a   Kim, HeeCheol ^a   Yun, Seong Hyeon ^a   Lee, Woo Yong ^a   Chun, Ho Kyung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Adjuvant chemotherapy; Stage IIA colon cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; UFT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; TEGAFUR; URACIL;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; COLON OBSTRUCTION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; GENDER; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS RESECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR DIFFERENTIATION; ADJUVANT CHEMOTHERAPY; CANCER STAGING; CHI SQUARE DISTRIBUTION; COLON RESECTION; COLON TUMOR; FEMALE; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; MALE; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; COLECTOMY; COLONIC NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME; URACIL;

EID: 84872060986     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10260     Document Type: Article

References (31)

1. Ota D, Nelson H: The surgeon and adjuvant therapy for stage II colon cancer. Ann Surg Oncol 2007; 14:272-273.
2. Swanson RS, Compton CC, Stewart AK, Bland KI: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003; 10:65-71.
3. O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96:1420-1425.
4. Morris M, Platell C, McCaul K, et al.: Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. Int J Colorectal Dis 2007; 22:887-895.
5. Sakamoto I, Ohashi Y, Hamada C, et al.: Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22:484-492.
6. Glimelius B, Dahl O, Cedermark B, et al.: Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomized trials by the nordic gastrointestinal tumour adjuvant therapy group. Acta Oncol 2005; 44:904-912.
7. Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB: Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002; 20:3999-4005.
8. Mamounas E, Wieand S, Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17:1349-1355.
9. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L: Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004; 22:3395-3407.
10. Sakamoto J, Hamada C, Kodaira S, Nakazato H, Ohashi Y: Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials. Jpn J Clin Oncol 1999; 29:78-86.
11. Lembersky BC, Wieand HS, Petrelli NJ, et al.: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from national surgical adjuvant breast and bowel project protocol C-06. J Clin Oncol 2006; 24:2059-2064.
12. Kim DJ, Kim TI, Suh JH, et al.: Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer. Yonsei Med J 2003; 44:665-675.
13. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP: American joint committee on cancer prognostic factors consensus conference: colorectal working group. Cancer 2000; 88.1739-1757.
14. Le Voyer TE, Sigurdson ER, Hanlon AL, et al.: Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21:2912-2919.
15. Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurun J, Virnig BA: Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 2005; 97:219-225.
16. Morris E, Maughan NJ, Forman D, Quirke P: Who to treat with adjuvant therapy in Dukes B/Stage II colorectal cancer? - The need for high quality pathology. Gut 2007; 56(10):1419-1425.
17. Burdy G, Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P: Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001; 44:1682-1688.
18. Prandi M, Lionetto R, Bini A, et al.: Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 2002; 235:458-463.
19. Scheithauer W, McKendrick J, Begbie S, et al.: Oral capecitabine as an alternative to i.v. 5-fiuorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14:1735-1743.
20. Andre T, Sargent D, Tabernero J, et al.: Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 2006; 13:887-898.
21. Tepper JE, O'Connell MJ, Niedzwiecki D, et al.: Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001; 19:157-163.
22. Wong JH, Severino R, Honnebier MB, Tom P, Namiki TS: Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol 1999; 17:2896-2900.
23. Sarli L, Bader G, Iusco D, et al.: Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer 2005; 41:272-279.
24. International multi-centre pooled analysis of B2 colon cancer trials (IMPACT B2) investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999; 17:1356-1363.
25. Petersen VC, Baxter KJ, Love SB, Shepherd NA: Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002; 51:65-69.
26. Buyse M, Piedbois P: Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001; 28:20-24.
27. Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312:1604-1608.
28. Kopec JA, Yothers G, Ganz PA, et al.: Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007; 25:424-430.
29. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-2351.
30. Twelves C, Wong A, Nowacki MP, et al.: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352:2696-2704.
31. Walko CM, Lindley C: Capecitabine: a review. Clin Ther 2005; 27:23-44.